A4362212
FG-4592 , ≥98% , 808118-40-3
CAS NO.：808118-40-3
Empirical Formula: C19H16N2O5
Molecular Weight: 352.34
MDL number: MFCD20040519
EINECS: 813-400-2
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB343.20 | In Stock |
|
| 50MG | RMB1040.00 | In Stock |
|
| 250MG | RMB2445.60 | In Stock |
|
| 500mg | RMB3839.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 199-215°C |
| Boiling point: | 684.3±55.0 °C(Predicted) |
| Density | 1.389 |
| storage temp. | -20°C |
| solubility | Soluble in DMSO (up to at least 25 mg/ml). |
| form | solid |
| pka | 2.46±0.10(Predicted) |
| color | Off-white or white |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| InChI | InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23) |
| InChIKey | YOZBGTLTNGAVFU-UHFFFAOYSA-N |
| SMILES | C(O)(=O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC1=CC=CC=C1)C=C2)=O |
Description and Uses
Roxadustat is an orally administered, small molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by FibroGen, in collaboration with Astellas and AstraZeneca, for the treatment of anaemia in patients with dialysis-dependent chronic kidney disease (CKD), non-dialysis-dependent CKD and in patients with myelodysplastic syndromes.
Roxadustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor used to increase white blood cell levels in blood and hematopoietic progenitor cells in bone marrow.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H319-H302-H315-H332-H335 |
| Precautionary statements | P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312 |
